Ardelyx (ARDX) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0396971071
Ardelyx, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines to treat gastrointestinal and cardiorenal diseases. Their primary goal is to improve the lives of patients suffering from these conditions.
The company's lead product candidate, tenapanor, is designed to treat patients with irritable bowel syndrome with constipation (IBS-C). This condition affects millions of people worldwide, causing uncomfortable symptoms like abdominal pain, bloating, and changes in bowel movements. Tenapanor has the potential to provide relief to these patients.
In addition to tenapanor, Ardelyx is developing XPHOZAH, a medication in Phase III clinical trials aimed at reducing high levels of phosphorus in the blood of adults with chronic kidney disease (CKD) who are on dialysis. Elevated phosphorus levels can lead to serious health complications, including heart disease and bone damage.
Ardelyx is also working on RDX013, a potassium secretagogue that targets hyperkalemia, a condition characterized by elevated potassium levels in the blood. This condition is common in patients with kidney and/or heart failure, and can lead to life-threatening complications if left untreated.
The company is also developing RDX020, a treatment for metabolic acidosis, a serious electrolyte disorder that can cause a range of symptoms, including fatigue, muscle weakness, and rapid breathing.
Ardelyx has established partnerships with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. to develop and commercialize tenapanor in their respective territories. These collaborations will help expand the reach of Ardelyx's innovative medicines to more patients worldwide.
Headquartered in Waltham, Massachusetts, Ardelyx, Inc. was founded in 2007 and was formerly known as Nteryx, Inc. before changing its name in 2008. For more information about the company and its mission, visit their website at https://www.ardelyx.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ARDX Stock Overview
Market Cap in USD | 1,876m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2014-06-19 |
ARDX Stock Ratings
Growth 5y | 3.50 |
Fundamental | -53.1 |
Dividend | - |
Rel. Performance vs Sector | 6.11 |
Analysts | 4.80/5 |
Fair Price Momentum | 7.73 USD |
Fair Price DCF | - |
ARDX Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ARDX Growth Ratios
Growth 12m | 120.00% |
Growth Correlation 12m | 60% |
Growth Correlation 3m | -47% |
CAGR 5y | 22.00% |
CAGR/Mean DD 5y | 0.47 |
Sharpe Ratio 12m | 1.51 |
Alpha vs SP500 12m | 87.66 |
Beta vs SP500 5y weekly | 1.17 |
ValueRay RSI | 51.65 |
Volatility GJR Garch 1y | 99.06% |
Price / SMA 50 | 4.27% |
Price / SMA 200 | 27.2% |
Current Volume | 2291k |
Average Volume 20d | 5887.1k |
External Links for ARDX Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 19, 2024, the stock is trading at USD 7.81 with a total of 2,291,027 shares traded.
Over the past week, the price has changed by +0.51%, over one month by +19.24%, over three months by -13.61% and over the past year by +98.73%.
According to ValueRays Forecast Model, ARDX Ardelyx will be worth about 8.7 in May 2025. The stock is currently trading at 7.81. This means that the stock has a potential upside of +10.76%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 14 | 78.6 |
Analysts Target Price | 9.8 | 25.6 |
ValueRay Target Price | 8.7 | 10.8 |